Drug Interactions Database

6278 interactions from BNF 85 - Check your medicines

Source: BNF 85
oxcarbazepine simvastatin

decreases exposure

Unknown Theoretical
oxcarbazepine sorafenib

decreases exposure

Unknown Study
oxcarbazepine statins

decreases exposure

Unknown Theoretical
oxybutynin zonisamide

increases risk of overheatinganddehydration

Unknown Theoretical
oxymetholone coumarins

increases anticoagulant effect

Unknown Anecdotal
oxymetholone phenindione

increases anticoagulant effect

Unknown Anecdotal
ozanimod theactivemetabolitesofozanimod

increases exposure

Unknown Theoretical
palbociclib benzodiazepines

increases exposure

Unknown Study
palbociclib midazolam

increases exposure

Unknown Study
pancreatin acarbose

decreases effects

Unknown Theoretical
pancuronium digoxin

increases risk of cardiovascularadverseeffects

Unknown Anecdotal
pantoprazole alpelisib

increases exposure

Unknown Theoretical
paracetamol coumarins

increases anticoagulant effect

Unknown Study
paracetamol dapsone

increases risk of methaemoglobinaemia

Unknown Theoretical
paroxetine antipsychotics,secondgeneration

increases exposure

Unknown Study
paroxetine asenapine

increases exposure

Unknown Study
pazopanib atorvastatin

affects exposure

Unknown Theoretical
pazopanib lomitapide

increases exposure

Unknown Theoretical
pazopanib phenindione

increases risk of bleedingevents

Unknown Theoretical
pazopanib pravastatin

affects exposure

Unknown Theoretical
pazopanib rosuvastatin

affects exposure

Unknown Theoretical
pazopanib statins

affects exposure

Unknown Theoretical
pazopanib theactivecomponentofsacituzumabgovitecan

increases exposure

Unknown Theoretical
pegaspargase imatinib

increases risk of hepatotoxicity

Unknown Theoretical
pegaspargase methotrexate

affects efficacy

Unknown Anecdotal
pegaspargase vincaalkaloids

increases risk of neurotoxicity

Unknown Anecdotal
pegaspargase vincristine

increases risk of neurotoxicity

Unknown Anecdotal
pemigatinib alkylatingagents

decreases exposure

Unknown Theoretical
pemigatinib colchicine

increases exposure

Unknown Theoretical
pemigatinib cyclophosphamide

increases exposure

Unknown Theoretical
pemigatinib dabigatran

increases exposure

Unknown Theoretical
pemigatinib digoxin

increases exposure

Unknown Theoretical
pemigatinib everolimus

increases exposure

Unknown Theoretical
pemigatinib ifosfamide

decreases exposure

Unknown Theoretical
pemigatinib methadone

decreases exposure

Unknown Theoretical
pemigatinib opioids

decreases exposure

Unknown Theoretical
pemigatinib phosphate

increases risk of hyperphosphataemia

Unknown Theoretical
pemigatinib sirolimus

increases exposure

Unknown Theoretical
pemigatinib theactivemetaboliteofalkylatingagents

increases exposure

Unknown Theoretical
pemigatinib theactivemetaboliteofcyclophosphamide

increases exposure

Unknown Theoretical
pemigatinib thrombininhibitors

increases exposure

Unknown Theoretical
penicillamine digoxin

decreases concentration

Unknown Anecdotal
penicillins phenindione

increases risk of bleedingevents

Unknown Theoretical
peppermintoil lomitapide

increases exposure

Unknown Theoretical
phenobarbital antifungals,azoles

decreases concentration

Unknown Study
phenobarbital itraconazole

decreases concentration

Unknown Study
phenothiazines amfetaminesandamfetaminesarepredictedtodecreasetheeffectsofphenothiazines

decreases effects

Unknown Study
phenytoin aminophylline

decreases exposure

Unknown Study
phenytoin anaesthetics,local

decreases exposure

Unknown Theoretical
phenytoin antifungals,azoles

decreases exposure

Unknown Study
Important: This database uses data from the British National Formulary (BNF 85). It is for informational purposes only and is not a substitute for professional medical advice.